decompensated heart failure

Decompensated heart failure (often termed 'acute decompensated heart failure' or ADHF) occurs when a patient with chronic heart failure experiences an acute exacerbation, or when new-onset heart failure presents acutely. Pathophysiologically, it reflects the failure of compensatory mechanisms (RAAS activation, sympathetic nervous system stimulation, natriuretic peptide release) to maintain adequate cardiac output, resulting in either volume overload (congestion) or hypoperfusion (cardiogenic shock in severe cases).

Common precipitants include dietary indiscretion (excess sodium/fluid intake), medication non-adherence, myocardial ischemia/infarction, arrhythmias (especially atrial fibrillation), uncontrolled hypertension, infections, renal failure, pulmonary embolism, and NSAID or thiazolidinedione use.

Clinical presentation varies by hemodynamic profile, classically categorized using the Stevenson classification based on congestion (wet/dry) and perfusion (warm/cold): - Warm & wet: most common, presents with dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, jugular venous distension, pulmonary crackles, S3 gallop - Cold & wet: congestion plus poor perfusion (cool extremities, altered mental status, hypotension) - Warm & dry: compensated - Cold & dry: rare, low output without congestion

Diagnostic workup includes BNP/NT-proBNP (elevated), chest X-ray (pulmonary edema, cardiomegaly, pleural effusions), echocardiogram (assess EF, wall motion), ECG (identify ischemia/arrhythmia), and basic metabolic panel (renal function, electrolytes).

Management focuses on the 'wet vs dry, warm vs cold' framework: - Diuretics (IV loop diuretics like furosemide) for volume overload - Vasodilators (nitroglycerin, nitroprusside) for afterload reduction if blood pressure permits - Inotropes (dobutamine, milrinone) for cardiogenic shock/cold extremities - Address underlying precipitant - Consider mechanical support (IABP, LVAD) or advanced therapies if refractory

Progression to cardiogenic shock represents severe decompensation with end-organ hypoperfusion, carrying high mortality. Long-term management requires optimizing guideline-directed medical therapy (ACE-I/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors) to prevent recurrent decompensation.